Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome

Objective:S100A12 is a pro-inflammatory protein that is secreted by granulocytes. S100A12 serum levels increase during inflammatory bowel disease (IBD). We performed the first study analysing faecal S100A12 in adults with signs of intestinal inflammation.Methods:Faecal S100A12 was determined by ELIS...

Full description

Saved in:
Bibliographic Details
Published in:Gut 2007-12, Vol.56 (12), p.1706-1713
Main Authors: Kaiser, T, Langhorst, J, Wittkowski, H, Becker, K, Friedrich, A W, Rueffer, A, Dobos, G J, Roth, J, Foell, D
Format: Article
Language:English
Subjects:
Accuracy
Adolescent
Adult
Aged
Aged, 80 and over
Bacterial Infections - diagnosis
Biological and medical sciences
Biomarkers
Biomarkers - analysis
Biopsy
Child
Child, Preschool
Colitis, Ulcerative - diagnosis
Colleges & universities
Colon
Crohn Disease - diagnosis
Crohn's disease
Diagnosis, Differential
Endoscopy
Feces - chemistry
Female
Gastroenteritis - diagnosis
Gastroenterology. Liver. Pancreas. Abdomen
Granulocytes
Histology
Humans
Infant
Inflammation
Inflammatory Bowel Disease
Inflammatory Bowel Diseases - diagnosis
Irritable bowel syndrome
Irritable Bowel Syndrome - diagnosis
Leukocyte L1 Antigen Complex - analysis
Male
Medical sciences
Middle Aged
Neutrophils
Other diseases. Semiology
Patients
Prospective Studies
Proteins
Rodents
S100 Proteins - analysis
S100A12 Protein
Sensitivity and Specificity
Severity of Illness Index
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Virus Diseases - diagnosis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective:S100A12 is a pro-inflammatory protein that is secreted by granulocytes. S100A12 serum levels increase during inflammatory bowel disease (IBD). We performed the first study analysing faecal S100A12 in adults with signs of intestinal inflammation.Methods:Faecal S100A12 was determined by ELISA in faecal specimens of 171 consecutive patients and 24 healthy controls. Patients either suffered from infectious gastroenteritis confirmed by stool analysis (65 bacterial, 23 viral) or underwent endoscopic and histological investigation (32 with Crohn’s disease, 27 with ulcerative colitis, and 24 with irritable bowel syndrome; IBS). Intestinal S100A12 expression was analysed in biopsies obtained from all patients. Faecal calprotectin was used as an additional non-invasive surrogate marker.Results:Faecal S100A12 was significantly higher in patients with active IBD (2.45 ± 1.15 mg/kg) compared with healthy controls (0.006 ± 0.03 mg/kg; p
ISSN:0017-5749
1468-3288
DOI:10.1136/gut.2006.113431